Brown/LUNGevity Award to Understand Mechanisms of Resistance to Immunotherapy

The research funded through this award is expected to have a direct clinical impact on patients with NSCLC whose tumors have progressed on currently approved immunotherapy regimens. Through this RFA mechanism, LUNGevity is interested in answering these questions:

• How do cells escape immunotherapy after an initial response, i.e., what is/are the mechanism(s) causing acquired resistance to immunotherapy?

• What’s next for patients whose tumors have progressed after first-line immunotherapy regimens?